论文部分内容阅读
目的探讨曲美他嗪治疗不稳定型心绞痛的临床疗效。方法回顾分析63例患者的临床资料。结果观察组和对照组治疗后总有效率分别为93.94%(31/33)、70.0%(21/30),临床疗效差异有统计学意义(P<0.05)。患者治疗过程中肝、肾功能均无明显变化,未出现明显肌痛、无力及转氨酶、肌酶升高等不良反应。结论曲美他嗪治疗不稳定型心绞痛疗效确切,不良反应小,安全可靠。
Objective To investigate the clinical efficacy of trimetazidine in the treatment of unstable angina pectoris. Methods The clinical data of 63 patients were retrospectively analyzed. Results The total effective rates of the observation group and the control group after treatment were 93.94% (31/33) and 70.0% (21/30), respectively. There were significant differences in clinical efficacy between the two groups (P <0.05). During the course of treatment, there was no significant change in liver and kidney function, no obvious myalgia, weakness, and adverse reactions such as transaminase and muscle enzymes. Conclusion Trimetazidine treatment of unstable angina pectoris has definite curative effect, little adverse reaction, safe and reliable.